Table 1.
Baseline demographics, clinical characteristics, treatment profile, and disease activity for patients with RA who initiated TCZ with MTX
| Characteristics | All TCZ initiators (N = 444) |
|---|---|
| Age, mean (SD), years | 57.3 (12.7) |
| Female, n (%) | 367 (82.7) |
| Race, n (%) | |
| White | 369 (83.7) |
| Black | 21 (4.8) |
| Asian | 11 (2.5) |
| Other | 40 (9.1) |
| Smoking status, n (%) | |
| Current | 67 (15.2) |
| Previous | 130 (29.5) |
| Never | 244 (55.3) |
| Weight, mean (SD), lb | 185.5 (50.3) |
| BMI category, n (%) | |
| Normal/underweight (< 25 kg/m2) | 105 (23.6) |
| Overweight (≥ 25 to < 30 kg/m2) | 131 (29.5) |
| Obese (≥ 30 kg/m2) | 208 (46.8) |
| Insurance, n (%)a | |
| Private | 338 (76.1) |
| Medicaid | 22 (5.0) |
| Medicare | 158 (35.6) |
| None | 4 (0.9) |
| Disease duration, mean (SD), years | 11.6 (9.3) |
| History of comorbidities, n (%) | |
| Hypertension | 131 (29.5) |
| Diabetes | 49 (11.0) |
| Malignancyb | 35 (7.9) |
| Cardiovascular diseasec | 160 (36.0) |
| No. of prior non-MTX csDMARDs, n (%)d,e | |
| 0 | 240 (54.1) |
| 1 | 109 (24.5) |
| ≥ 2 | 95 (21.4) |
| No. of prior biologics, n (%)d,f | |
| 0 | 26 (5.9) |
| 1 | 123 (27.7) |
| ≥ 2 | 295 (66.4) |
| Current prednisone use, n (%) | 158 (35.6) |
| Prednisone dose, mean (SD), mgg | 7.1 (5.4) |
| MTX dose, mean (SD), mg | 17.7 (5.8) |
| CDAI score, mean (SD) | 24.0 (15.4) |
| DAS28, mean (SD) | 4.3 (1.6) |
| Tender joint count (0–28), mean (SD) | 8.8 (8.1) |
| Swollen joint count (0–28), mean (SD) | 6.3 (6.2) |
| Physician global assessment (VAS 0–100), mean (SD) | 38.5 (22.2) |
| Patient global assessment (VAS 0–100), mean (SD) | 50.2 (25.5) |
| mHAQ, mean (SD) | 0.6 (0.5) |
| Patient pain (VAS 0–100), mean (SD) | 52.3 (26.2) |
| Patient fatigue (VAS 0–100), mean (SD) | 55.0 (27.9) |
| Morning stiffness present, n (%) | 368 (89.8) |
| Morning stiffness duration, mean (SD), hh | 1.9 (3.2) |
BMI body mass index, CABG coronary artery bypass grafting, CDAI Clinical Disease Activity Index, CHF congestive heart failure, csDMARD conventional synthetic disease-modifying antirheumatic drug, CV cardiovascular, DAS28 Disease Activity Score in 28 joints, mHAQ modified Health Assessment Questionnaire, MTX methotrexate, RA rheumatoid arthritis, TCZ tocilizumab, VAS visual analog scale
aTotals may not add up to 100% since patients may have had > 1 type of insurance
bMalignancy includes breast cancer, lung cancer, lymphoma, skin cancer (melanoma and squamous cell), and other cancers
cHistory of cardiovascular disease includes history of hypertension, hyperlipidemia, cardiac revascularization procedure (CABG, stent, angioplasty), ventricular arrhythmia, cardiac arrest, myocardial infarction, acute coronary syndrome, unstable angina, other coronary artery disease, CHF (with and without hospitalization), stroke, transient ischemic attack, other CV, deep vein thrombosis, peripheral arterial disease, peripheral arterial thrombosis, urgent peripheral revascularization, peripheral ischemia/gangrene, pulmonary embolism, carotid artery disease, and hemorrhage
dIncluding past and current therapies
ecsDMARDs: hydroxychloroquine, leflunomide, sulfasalazine, azathioprine, minocycline, and cyclosporine
fBiologics: adalimumab, etanercept, certolizumab pegol, golimumab, infliximab, anakinra, sarilumab, abatacept, rituximab, and tofacitinib
gAmong prednisone users
hAmong those experiencing morning stiffness